Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

by Zacks Equity Research

Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.

    Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

    by Zacks Equity Research

    Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.

      Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

      by Zacks Equity Research

      Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

        Arpita Dutt headshot

        FDA Approvals Surge in 2017: Here's a Look at the Numbers

        by Arpita Dutt

        There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers and what lies ahead.

          GE Healthcare Partners Roche for Improved Critical Care

          by Zacks Equity Research

          General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.

            Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial

            by Zacks Equity Research

            Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.

              ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632

              by Zacks Equity Research

              ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.

                Cancer Space Update: New Regulatory Status for 3 Major Drugs

                by Zacks Equity Research

                Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.

                  Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

                  by Zacks Equity Research

                  Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals

                    by Arpita Dutt

                    In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.

                      3 Large-Cap Pharma Stocks to Watch Out for This New Year

                      by Zacks Equity Research

                      We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.

                        Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?

                        by Zacks Equity Research

                        AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.

                          Novartis Gets Second Breakthrough Designation for Kisqali

                          by Zacks Equity Research

                          Novartis (NVS) announces that the FDA has granted the second breakthrough designation to breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

                            Swarup Gupta headshot

                            Foreign Stock Roundup: Roche to Buy Ignyta for $1.7B; Shell to Acquire First Utility

                            by Swarup Gupta

                            Global markets traversed a holiday shortened week marked by thin trading volumes.

                              Arpita Dutt headshot

                              3 Biotech and Pharma Stocks with FDA Catalysts this January

                              by Arpita Dutt

                              2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

                                The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

                                  4 Large-Cap Pharma Stocks That Outperformed the S&P This Year

                                  by Zacks Equity Research

                                  We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.

                                    ImmunoGen (IMGN) Soars Above 200% This Year: Here's Why

                                    by Zacks Equity Research

                                    ImmunoGen's (IMGN) shares shoot up in the year on rapid pipeline progress, positive study data and strategic collaborations.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis

                                      by Arpita Dutt

                                      Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.

                                        Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?

                                        by Zacks Equity Research

                                        Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.

                                          Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?

                                          by Zacks Equity Research

                                          Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.

                                            Roche (RHHBY) Clinches $1.7-Billion Deal to Acquire Ignyta

                                            by Zacks Equity Research

                                            Roche (RHHBY) is set to acquire Ignyta for $27 per share or a total value of $1.7 billion to strengthen its oncology pipeline further.

                                              Celgene (CELG) Down on Discouraging Data on Revlimid

                                              by Zacks Equity Research

                                              Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.

                                                Cancer Space Update: FDA Approves Label Expansion of 4 Drugs

                                                by Zacks Equity Research

                                                The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.

                                                  Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer

                                                  by Zacks Equity Research

                                                  Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence